Unknown

Dataset Information

0

Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual ?-cell function in recent-onset type 1 diabetes.


ABSTRACT: Immune intervention trials in recent-onset type 1 diabetes would benefit from biomarkers associated with good therapeutic response. In the previously reported randomized placebo-controlled anti-CD3 study (otelixizumab; GlaxoSmithKline), we tested the hypothesis that specific diabetes autoantibodies might serve this purpose.In the included patients (n = 40 otelixizumab, n = 40 placebo), ?-cell function was assessed as area under the curve (AUC) C-peptide release during a hyperglycemic glucose clamp at baseline (median duration of insulin treatment: 6 days) and every 6 months until 18 months after randomization. (Auto)antibodies against insulin (I[A]A), GAD (GADA), IA-2 (IA-2A), and ZnT8 (ZnT8A) were determined on stored sera by liquid-phase radiobinding assay.At baseline, only better preserved AUC C-peptide release and higher levels of IAA were associated with better preservation of ?-cell function and lower insulin needs under anti-CD3 treatment. In multivariate analysis, IAA (P = 0.022) or the interaction of IAA and C-peptide (P = 0.013) independently predicted outcome together with treatment. During follow-up, good responders to anti-CD3 treatment (i.e., IAA(+) participants with relatively preserved ?-cell function [? 25% of healthy control subjects]) experienced a less pronounced insulin-induced rise in I(A)A and lower insulin needs. GADA, IA-2A, and ZnT8A levels were not influenced by anti-CD3 treatment, and their changes showed no relation to functional outcome.There is important specificity of IAA among other diabetes autoantibodies to predict good therapeutic response of recent-onset type 1 diabetic patients to anti-CD3 treatment. If confirmed, future immune intervention trials in type 1 diabetes should consider both relatively preserved functional ?-cell mass and presence of IAA as inclusion criteria.

SUBMITTER: Demeester S 

PROVIDER: S-EPMC4370324 | biostudies-literature | 2015 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Preexisting insulin autoantibodies predict efficacy of otelixizumab in preserving residual β-cell function in recent-onset type 1 diabetes.

Demeester Simke S   Keymeulen Bart B   Kaufman Leonard L   Van Dalem Annelien A   Balti Eric V EV   Van de Velde Ursule U   Goubert Patrick P   Verhaeghen Katrijn K   Davidson Howard W HW   Wenzlau Janet M JM   Weets Ilse I   Pipeleers Daniel G DG   Gorus Frans K FK  

Diabetes care 20150112 4


<h4>Objective</h4>Immune intervention trials in recent-onset type 1 diabetes would benefit from biomarkers associated with good therapeutic response. In the previously reported randomized placebo-controlled anti-CD3 study (otelixizumab; GlaxoSmithKline), we tested the hypothesis that specific diabetes autoantibodies might serve this purpose.<h4>Research design and methods</h4>In the included patients (n = 40 otelixizumab, n = 40 placebo), β-cell function was assessed as area under the curve (AUC  ...[more]

Similar Datasets

| S-EPMC5697953 | biostudies-literature
| S-EPMC6280838 | biostudies-other
2012-05-31 | E-GEOD-33440 | biostudies-arrayexpress
| S-EPMC8130764 | biostudies-literature
2019-02-28 | GSE124400 | GEO
2012-06-01 | GSE33440 | GEO
| S-EPMC4138247 | biostudies-literature
2022-01-01 | GSE156035 | GEO
| S-EPMC6478408 | biostudies-literature
| S-EPMC6024554 | biostudies-literature